COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Levetiracetam for Painful Polyneuropathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00286260
Recruitment Status : Completed
First Posted : February 3, 2006
Last Update Posted : December 18, 2009
Information provided by:
Odense University Hospital

Brief Summary:
Polyneuropathy of different etiologies is often associated with pain. The standard treatment of this pain is anticonvulsants or antidepressants, but none of these treatment are effective or tolerable for all patients. Levetiracetam is a newer anticonvulsant and it is the hypothesis is that it could relieve neuropathic pain in polyneuropathy. This is a randomised, double-blind, placebo-controlled, cross-over trial on the effect of levetiracetam 3.000 mg/day on pain in polyneuropathy

Condition or disease Intervention/treatment Phase
Painful Polyneuropathy Drug: levetiracetam Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Double-blind, Randomised, Placebo-controlled Trial of the Effect of Levetiracetam on Painful Polyneuropathy
Study Start Date : January 2006
Actual Primary Completion Date : August 2008
Actual Study Completion Date : October 2008

Resource links provided by the National Library of Medicine

Intervention Details:
  • Drug: levetiracetam
    Levetiracetam tablet 500 mg, daily dose titrated to 3000 mg, 6 weeks

Primary Outcome Measures :
  1. Pain relief rated on a 0 to 10 point numeric rating scale (median value for last treatment week in each period) [ Time Frame: Daily ]

Secondary Outcome Measures :
  1. Pain rated on 0 to 10 point numeric rating scales [ Time Frame: Daily ]
  2. Pain subtypes rated on 0 to 10 point numeric rating scales [ Time Frame: Daily ]
  3. Bruch-evoked pain [ Time Frame: Baseline and end of each treament period ]
  4. Pin-prick evoked pain [ Time Frame: Baseline and end of each treatment period ]
  5. Cold evoked pain [ Time Frame: Baseline and end of each treatment period ]
  6. Health related quality of life(SF-36) [ Time Frame: Baseline and end of each treatment period ]
  7. Pain related sleep disturbance [ Time Frame: Daily ]
  8. Use of escape medication [ Time Frame: Daily ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age 20 to 0 years
  • painful symptoms of polyneuropathy for at least 6 months
  • confirmed diagnosis of polyneuropathy
  • baseline pain score of 4 or more (0 to 10 point scale)
  • pain at least 4 days a week
  • adequate anticonceptive treatment for women with childbearing potential
  • informed consent

Exclusion Criteria:

  • other cause of pain
  • previous allergic reactions towards levetiracetam
  • known adverse drug reactions on levetiracetam
  • pregnancy
  • severe disease
  • inability to follow study protocol
  • treatment with antidepressants, other anticonvulsants or opioids

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00286260

Layout table for location information
Department of Neurology, Odense University Hospital
Odense C, Denmark, DK-5000
Sponsors and Collaborators
Odense University Hospital
Layout table for investigator information
Study Chair: Søren H Sindrup, Professor Department of Neurology, Odense Unviersity Hospital
Layout table for additonal information
Responsible Party: Professor Søren H. Sindrup, Odense University Hospital Identifier: NCT00286260    
Other Study ID Numbers: keppra2
First Posted: February 3, 2006    Key Record Dates
Last Update Posted: December 18, 2009
Last Verified: January 2006
Keywords provided by Odense University Hospital:
neuropathic pain
Additional relevant MeSH terms:
Layout table for MeSH terms
Neurologic Manifestations
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Nootropic Agents